What is revenue-based financing?
An advance repaid as a share of revenue until a fixed cap is reached. The provider funds an amount today; the business pays over a percentage of its monthly revenue, commonly 5% to 15%, until it has repaid a fixed multiple of the advance, with caps commonly running 1.5x to 3.0x (Re:cap, revenue-based financing guide, accessed 6 September 2026). No fixed term, no fixed payment, no covenant package in the conventional sense: the repayment schedule is whatever the revenue makes it.
The instrument exists for businesses whose value sits in recurring or contracted revenue rather than hard assets or accumulated EBITDA: software, subscriptions, contracted services. For a founder who does not want to sell equity and cannot yet support conventional debt, the pitch is speed, no dilution, and payments that flex with the business. All three parts of the pitch are true. The price of them is the subject of this article.
One taxonomy point prevents a category of expensive confusion: fixed-share revenue-based financing is not the same instrument as the recurring-revenue term facilities that larger software companies raise from direct lenders, which carry conventional terms sized off annual recurring revenue and convert to earnings-based covenants at scale. The two share a vocabulary and almost nothing else. This article concerns the first; a business large enough for the second is shopping in a different market.
What does the cap actually cost?
The quoted multiple is not a rate, and converting it into one is the single most important piece of work a borrower can do before signing. The mechanism is counterintuitive: because the cap is fixed, the total cost in dollars never changes, so the faster it is repaid, the higher the annualized cost of the money. A 1.3x cap repaid over eighteen months works out to roughly a 25% effective annual rate; the same cap repaid over thirty-six months is under 15% (Re:cap, revenue-based financing guide, accessed 6 September 2026).
Sit with the direction of that for a moment, because it is the opposite of every instrument elsewhere in the capital stack. A business that beats its plan repays the cap sooner and therefore pays a higher rate, precisely because it did well. The effective market range runs 15% to 40% (Re:cap, same source), and where a given borrower lands inside it is decided mostly by its own growth, after signing, when nothing about the price can be renegotiated.
That is not an argument that the instrument is mispriced; it is an argument that the price is unknowable at signing unless you model it. The provider has modelled it. The borrower who has not is the only party at the table who does not know what the money costs.
| Repayment period | Effective annual rate | What produced it |
|---|---|---|
| 18 months | About 25% | Revenue ahead of plan; the fixed cap repaid quickly |
| 36 months | Under 15% | Slower revenue; the same dollars over twice the time |
| Market range observed | 15% to 40% | Where growth outcomes land borrowers across the market |
“Every other lender in the stack earns less when you repay early. This one earns more, at an annualized rate, the better your business performs. That is not a criticism. It is the term sheet, and it deserves to be read as one.”
How do you convert a cap into a rate?
Mechanically, and three times. Project the repayment schedule the revenue share implies under your base plan: month by month, the share applied to forecast revenue, until the cumulative repayment hits the cap. Compute the internal rate of return of that cash flow, monthly, and annualize it. That number, not the multiple, is the price of the money under your own plan, stated in the same units as every alternative you are comparing it against.
Then run it twice more: a downside case, where slower revenue stretches the repayment and the effective rate falls, and a flat case in between. The three numbers bracket what the financing will actually cost, and the spread between them is the instrument's real character: cheap if things go badly, expensive if they go well. Whether that is the right shape of risk for a given business is a legitimate question with defensible answers on both sides. It just has to be asked before signing rather than discovered after.
The comparison that completes the analysis is against the dilution the advance avoids. Equity sold today at today's valuation has a cost too, permanent and unpriced until the next round names it. A founder choosing revenue-based financing at a 25% effective rate over equity may be choosing well. The point is the word choosing: both costs computed, side by side, in the same units.
When does revenue-based financing fit, and when does it not?
It fits a specific moment: recurring revenue with demonstrated retention, a funding need well inside what the revenue supports, a use of proceeds that grows the business rather than fills a hole, and no institutional equity on the register to unlock cheaper venture debt. For that borrower, at modest size, the speed and the absence of dilution are worth a real premium over conventional debt the business could not raise anyway.
It does not fit as a habit. Sequential advances against the same revenue stream compound quietly: each new cap layers its own repayment share on the same revenue, and a business running two or three stacked advances can find a quarter of its top line committed to repayment before operating costs see a dollar. Stacking is the instrument's characteristic failure mode, and the discipline against it is a rule set in advance, not a judgement made under pressure.
And it stops fitting as the business scales. A company approaching the size where recurring-revenue term facilities or conventional structures become available is paying the small-company premium for money it no longer needs to buy expensively. The instrument done well is a bridge to cheaper capital, crossed once, in one direction.
What should a borrower negotiate?
The revenue definition, first. The share is applied to a defined term, and what that definition includes, gross receipts or net revenue, refunds and chargebacks, one-time against recurring items, moves the effective cost more cheaply than arguing the percentage. A loose definition is a dispute stored for the month it matters most.
The prepayment and refinancing mechanics, second. Because the cap is fixed, a borrower who refinances into cheaper capital mid-life pays the remaining cap unless the documents say otherwise, and some do: stepped caps that rise with time, or discounts for early settlement, change the arithmetic materially and are negotiable at signing. This is the term that decides whether the bridge to cheaper capital is crossable at a sensible toll.
And the share itself against the cap, understanding the trade: a lower share stretches repayment and lowers the effective rate at the same cap; a lower cap cuts the total cost at any speed. Providers price the two together, and a borrower who has run the three-scenario arithmetic knows which concession is worth more to its own plan, which is exactly the position the arithmetic exists to create.
As of September 2026
Sources: Re:cap, revenue-based financing guide, accessed 6 September 2026, for the effective-rate arithmetic on a 1.3x repayment cap over 18 and 36 months, the 15% to 40% effective annual rate range, revenue shares of 5% to 15% of monthly revenue, and repayment caps of 1.5x to 3.0x. The three-scenario conversion method described is our own practice, involves no market data, and is stated as advice rather than as a figure. The distinction between fixed-share revenue-based financing and recurring-revenue term facilities is market convention. Nothing in this article describes any transaction or engagement.
This position sits within our debt advisory practice.